Inovio Pharmaceuticals Inc (NASDAQ:INO) – Research analysts at Piper Jaffray Companies issued their Q1 2020 EPS estimates for shares of Inovio Pharmaceuticals in a research report issued on Tuesday, March 12th. Piper Jaffray Companies analyst C. Raymond expects that the biopharmaceutical company will earn ($0.31) per share for the quarter. Piper Jaffray Companies also issued estimates for Inovio Pharmaceuticals’ Q2 2020 earnings at ($0.31) EPS, Q3 2020 earnings at ($0.31) EPS and Q4 2020 earnings at ($0.29) EPS.
Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings data on Tuesday, March 12th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.03). Inovio Pharmaceuticals had a negative net margin of 318.11% and a negative return on equity of 88.61%. The company had revenue of $2.50 million for the quarter, compared to analyst estimates of $2.69 million. During the same quarter in the prior year, the company posted ($0.23) EPS.
Shares of NASDAQ INO opened at $3.62 on Thursday. Inovio Pharmaceuticals has a 1-year low of $3.02 and a 1-year high of $6.30. The stock has a market cap of $348.03 million, a PE ratio of -3.45 and a beta of 1.72.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Quantamental Technologies LLC acquired a new stake in shares of Inovio Pharmaceuticals in the 4th quarter worth about $43,000. Amalgamated Bank acquired a new stake in shares of Inovio Pharmaceuticals in the 4th quarter worth about $50,000. Pembroke Management LTD acquired a new stake in shares of Inovio Pharmaceuticals in the 4th quarter worth about $52,000. Fox Run Management L.L.C. acquired a new stake in shares of Inovio Pharmaceuticals in the 4th quarter worth about $58,000. Finally, Meeder Asset Management Inc. raised its holdings in shares of Inovio Pharmaceuticals by 522.6% in the 4th quarter. Meeder Asset Management Inc. now owns 14,718 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 12,354 shares during the last quarter. Institutional investors own 37.31% of the company’s stock.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.
Featured Story: Candlestick
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.